Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced ...

Jason Kelly is the cofounder and CEO of Ginkgo Bioworks. Ginkgo is a synthetic biology company headquartered in Boston that programs cells for customers in the chemical, pharmaceutical ...

For leading one of the region’s most intriguing public companies. Jason Kelly is the cofounder and CEO of Ginkgo Bioworks, a company that aims to program cells like computers. Ginkgo’s ...

This is where Ginkgo’s ecosystem is powerful, as it provides the computational tools that enable easier engineering. Sakalosky adds his insights based on when he first met Jason Kelly ...

Ginkgo Bioworks (NYSE ... attributable to biopharma customers by more than 50% over the past year," said Jason Kelly, Ginkgo's co-founder and chief executive officer. Ginkgo (DNA) ended 2023 ...

Jason Kelly, said in a statement. “We are sad to see them go.” Six weeks ago, Ginkgo reported lackluster earnings that, in Kelly’s words, necessitated “decisive action.” Revenue fell 53 ...

Ginkgo Bioworks Holdings ... The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings ... The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.